Literature DB >> 15657666

Injectable silicone biomaterial for fecal incontinence caused by internal anal sphincter dysfunction is effective.

J J Tjandra1, J F Lim, R Hiscock, P Rajendra.   

Abstract

PURPOSE: Fecal incontinence caused by a weak or disrupted internal anal sphincter is common but there has been no effective treatment. This prospective study evaluates the medium-term clinical effects of an injectable silicone biomaterial, PTP (Bioplastique), used to augment the internal anal sphincter.
METHOD: Eighty-two patients (64 females; median age, 66 years) with severe fecal incontinence and a low anal resting pressure caused by internal anal sphincter dysfunction (defect, n = 11; intact, n = 71) were randomized to PTP injection into intersphincteric space and internal anal sphincter with (Group A, n = 42) or without (Group B, n = 40) guidance by endoanal ultrasound. Both groups were similar in terms of age, gender, past anorectal surgery, duration of follow-up (median, 6 months; range, 1-12 months), and baseline continence score. Sixty-two percent of Group A and 55 percent of Group B had prolonged pudendal nerve terminal motor latency.
RESULTS: There was no significant complication. Two patients in Group A and four patients in Group B noted minor discomfort at injection sites. At one month postprocedure, endoanal ultrasound confirmed retention of silicone biomaterial without migration. In both groups, fecal continence was significantly improved by PTP implants 1 month after injection, but continued to improve significantly for up to 12 months in Group A and 6 months in Group B (P < 0.001). Improvement in fecal continence and maximum anal resting pressure was significantly greater in Group A, in whom injection was guided by endoanal ultrasound, than in Group B. At three months after injection, significantly more Group A patients than Group B patients achieved >50 percent improvement in Wexner's continence score (69 percent vs. 40 percent; P = 0.014). Ninety-three percent of Group A and 92 percent of Group B had >50 percent improvement in global quality of life scores (visual analog scale). At a median follow-up of 6 months, all domains of the fecal incontinence quality of life scale improved significantly in both groups; however, the physical function and mental health scores of Short Form-12 only improved in Group A. A prolonged pudendal nerve terminal motor latency had no effect on functional outcome in either group.
CONCLUSION: Injection of silicone biomaterial provided a marked improvement in fecal continence and quality of life in patients with internal sphincter dysfunction, despite the presence of pudendal neuropathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15657666     DOI: 10.1007/s10350-004-0760-3

Source DB:  PubMed          Journal:  Dis Colon Rectum        ISSN: 0012-3706            Impact factor:   4.585


  33 in total

1.  The greatest taboo: urinary incontinence as a source of shame and embarrassment.

Authors:  Ksenia Elenskaia; Karin Haidvogel; Christine Heidinger; Daniela Doerfler; Wolfgang Umek; Engelbert Hanzal
Journal:  Wien Klin Wochenschr       Date:  2011-09-22       Impact factor: 1.704

2.  Management of fecal incontinence.

Authors:  Adil E Bharucha
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-11

3.  Towards safer treatments for benign anorectal disease: the pharmacological manipulation of the internal anal sphincter.

Authors:  Oliver M Jones
Journal:  Ann R Coll Surg Engl       Date:  2007-09       Impact factor: 1.891

4.  In vivo growth of a bioengineered internal anal sphincter: comparison of growth factors for optimization of growth and survival.

Authors:  Eiichi A Miyasaka; Shreya Raghavan; Robert R Gilmont; Krittika Mittal; Sita Somara; Khalil N Bitar; Daniel H Teitelbaum
Journal:  Pediatr Surg Int       Date:  2011-02       Impact factor: 1.827

5.  Fecal incontinence.

Authors:  Tracy Hull
Journal:  Clin Colon Rectal Surg       Date:  2007-05

6.  Evaluation by three-dimensional anal endosonography of injectable silicone biomaterial (PTQ) implants to treat fecal incontinence: long-term localization and relation with the deterioration of the continence.

Authors:  F de la Portilla; J Vega; R Rada; M M Segovia-Gonzáles; N Cisneros; V H Maldonado; E Espinosa
Journal:  Tech Coloproctol       Date:  2009-07-15       Impact factor: 3.781

Review 7.  Current management of fecal incontinence: choosing amongst treatment options to optimize outcomes.

Authors:  Julie Ann M Van Koughnett; Steven D Wexner
Journal:  World J Gastroenterol       Date:  2013-12-28       Impact factor: 5.742

8.  Efficacy and quality of life 2 years after treatment for faecal incontinence with injectable bulking agents.

Authors:  J Danielson; U Karlbom; T Wester; W Graf
Journal:  Tech Coloproctol       Date:  2012-12-07       Impact factor: 3.781

9.  Clinical response and sustainability of treatment with temperature-controlled radiofrequency energy (Secca) in patients with faecal incontinence: 3 years follow-up.

Authors:  T J Lam; A P Visscher; M M Meurs-Szojda; R J F Felt-Bersma
Journal:  Int J Colorectal Dis       Date:  2014-05-08       Impact factor: 2.571

10.  Comparison of bulking agents in the treatment of fecal incontinence: a prospective randomized clinical trial.

Authors:  O J Morris; S Smith; B Draganic
Journal:  Tech Coloproctol       Date:  2013-03-23       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.